Do Extent of Resection and Tumor Volume affect the Overall Survival of Anaplastic Astrocytoma? A Retrospective Study from a Single Center

Dipak Chaulagain; Volodymyr Smolanka; Andriy Smolanka; Taras Havryliv

doi:10.3889/oamjms.2022.10697

Authors

Dipak Chaulagain Department of Neurosurgery, Uzhhorod Regional Clinical center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
Volodymyr Smolanka Department of Neurosurgery, Uzhhorod Regional Clinical center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
Andriy Smolanka Department of Neurosurgery, Uzhhorod Regional Clinical center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
Taras Havryliv Department of Neurosurgery, Uzhhorod Regional Clinical center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine

DOI:

https://doi.org/10.3889/oamjms.2022.10697

Keywords:

Anaplastic astrocytoma, Extent of resection, Survival rates, High grade glioma

Abstract

Introduction: Anaplastic astrocytoma (AA) is a rare brain neoplasm that belongs to grade III gliomas according to the World Health Organization (WHO) classification. It represents only 6% of all Central Nervous System (CNS) malignancies, yet; it is associated with low survival rates. We aim to identify the survival rate after tumor resection from 10 years of experience. We also wish to determine the effect of pre and post-operative tumor volumes on the overall survival (OS).

Methods: We retrospectively reviewed the records of patients with anaplastic astrocytoma who had surgery between January 2010 and January 2020. Based on Magnetic resonance imaging (MRI) results obtained < 72 hours after surgery, the Extent of Resection (EOR) was calculated by pre-op volume – post-op volume/pre-op volume*100% and classified into five categories. 1)>99% - Gross total resection (GTR) 2) 91-99% as Near-total resection (NTR) 3) 70-90% as Sub-total resection (STR) 4) <70% as Partial resection (PR) and 5) Biopsy. A multivariate proportional hazards regression analysis assessed the independent association of EOR and subsequent OS.

Results: 34 patients were finally included in our analysis. The median survival time for all patients was 24.4 months, whereas the histopathological type of AA like IDH mutant was 32 months, and IDH wild type was 16.1 months as OS time. We stratified the observed survival durations for the patients according to the EOR into 5 different classes. We found that the EOR didn't affect the overall median survival. Regression analysis showed no statistically significant association between the pre or post-operative tumor volume and the OS time.

Conclusion: Anaplastic astrocytoma is a tumor that carries a poor diagnosis. Gross total resection is essential to increase patients expected survival time. Unfortunately, the extent of tumor resection and tumor volume isn't correlated with the survival time for patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. https://doi.org/10.1007/s00401-007-0243-4 PMid:17618441 DOI: https://doi.org/10.1007/s00401-007-0243-4

Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, et al. Changing incidence and improved survival of gliomas. Eur J Cancer. 2014;50(13):2309-18. https://doi.org/10.1016/j.ejca.2014.05.019 PMid:24972545 DOI: https://doi.org/10.1016/j.ejca.2014.05.019

Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA. 2013;310(17):1842-50. https://doi.org/10.1001/jama.2013.280319 PMid:24193082 DOI: https://doi.org/10.1001/jama.2013.280319

Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncol. 2016;5(3):145-57. https://doi.org/10.2217/cns-2016-0002 PMid:27230974 DOI: https://doi.org/10.2217/cns-2016-0002

Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007- 2011. Neuro Oncol. 2014;16(14):iv1-63. https://doi.org/10.1093/neuonc/nou223 PMid:25304271 DOI: https://doi.org/10.1093/neuonc/nou223

Mathieu D, Fortin D. The role of chemotherapy in the treatment of malignant astrocytomas. Can J Neurol Sci. 2006;33(2):127-40. https://doi.org/10.1017/s0317167100004881 PMid:16736721 DOI: https://doi.org/10.1017/S0317167100004881

Gonzalez J, Gilbert MR. Treatment of astrocytomas. Curr Opin Neurol. 2005;18:632-8. https://doi.org/10.1097/01.wco.0000191510.14627.d2 PMid:16280673 DOI: https://doi.org/10.1097/01.wco.0000191510.14627.d2

Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol. 2007;63(1):72-80. https://doi.org/10.1016/j.critrevonc.2007.03.003 PMid:17478095 DOI: https://doi.org/10.1016/j.critrevonc.2007.03.003

Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J Clin Oncol. 1999;17(9):2762-71. https://doi.org/10.1200/JCO.1999.17.9.2762 PMid:10561351 DOI: https://doi.org/10.1200/JCO.1999.17.9.2762

Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2:552-60. https://doi.org/10.1016/S1470-2045(01)00489-2 PMid:11905710 DOI: https://doi.org/10.1016/S1470-2045(01)00489-2

McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156-62. https://doi.org/10.3171/2008.4.17536 PMid:18847342 DOI: https://doi.org/10.3171/2008.4.17536

Prados MD, Gutin PH, Phillips TL, Wara WM, Larson DA, Sneed PK, et al. Clinical original contribution highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989. J Radiat Oncol Biol Phys. 1992;23(1):3-8. https://doi.org/10.1016/0360-3016(92)90537-r PMid:1572829 DOI: https://doi.org/10.1016/0360-3016(92)90537-R

Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006;24(8):1253-65. https://doi.org/10.1200/JCO.2005.04.5302 PMid:16525180 DOI: https://doi.org/10.1200/JCO.2005.04.5302

Gupta R, Webb-Myers R, Flanagan S, Buckland ME. Isocitrate dehydrogenase mutations in diffuse gliomas: Clinical and aetiological implications. J Clin Pathol. 2011;64(10):835-44. https://doi.org/10.1136/jclinpath-2011-200227 PMid:21752797 DOI: https://doi.org/10.1136/jclinpath-2011-200227

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-12. https://doi.org/10.1126/science.1164382 PMid:18772396 DOI: https://doi.org/10.1126/science.1164382

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-43. https://doi.org/10.1200/JCO.2012.43.2674 PMid:23071247 DOI: https://doi.org/10.1200/JCO.2012.43.2674

Cho U, Yang SH, Yoo C. Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: An institutional experience. J Int Med Res. 2001;49(6):3000605211019258. https://doi.org/10.1177/03000605211019258 DOI: https://doi.org/10.1177/03000605211019258

Hardie JG, Kizilbash S, Buckner J, Parney I, Giannini C, Uhm J, et al. Factors contributing to survival in patients with anaplastic astrocytoma: A retrospective study of patients treated at a single institution. Int J Radiation Oncol. 2013;87(2):S104. https://doi.org/10.1016/j.ijrobp.2013.06.270 DOI: https://doi.org/10.1016/j.ijrobp.2013.06.270